Aqdot, a specialist chemical company with a focus in intelligent encapsulation, announces the appointment of Tim Wright as Chief Executive Officer.
Tim brings a wealth of experience having successfully developed, licensed and grown brands and businesses at all stages of their lifecycle. Prior to joining he co-founded Solent Pharma Ltd, a privately held speciality pharmaceutical company and has undertaken consulting projects supporting a variety of businesses as they develop growth and funding strategies. Previously Tim was CEO of IS Pharma plc, which he led through turnaround to become a substantial, profitable business. Tim has previously held senior domestic and international commercial roles with Élan, SmithKline Beecham and Pfizer.
Tim succeeds Dr John Hamlin, a company founder who has been CEO since 2012. John will remain actively involved and serve on the board as a non-executive director. John led Aqdot during its rapid growth from concept to a successful specialist chemical company that has raised in excess of £3.5m funding to date.
Dr Peter Fields, Non-Executive Chairman at Aqdot, said:
“We are delighted to have Tim join our team. His experience with early-stage companies and expertise in product and business development will prove invaluable as we develop and grow Aqdot.”
“On behalf of the Board I would like to extend our thanks to John for the vital role he has played in building Aqdot and I am very pleased that he will continue to work with the company as a director and advisor”.
Tim Wright, CEO at Aqdot, said:
“The combination of disruptive, proprietary technology, a world-class scientific team coupled with a strong, supportive board and investor group make this a very exciting opportunity. Our encapsulation technology will be game-changing across a number of high value sectors from household products to pharmaceuticals to oil and gas. I am delighted to be leading the Aqdot team as we drive the growth and value of the business.”
For further information, please contact:
Tim Wright, CEO
01223 334 319